Business Context and Reporting Period
Company: ASP Isotopes Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 26, 2026
Event: Entry into a Material Definitive Agreement involving the investment in Opeongo, Inc.
Key Financial Metrics and Transaction Details
This filing details a strategic investment rather than reporting standard operating financial metrics (revenue, profit, cash flow) for ASP Isotopes Inc. The filing text does not provide a clear value for ASP Isotopes' current revenue, profit, or liquidity.
| Metric | Value |
|---|---|
| Investment Target | Opeongo, Inc. (Biotechnology company) |
| Shares Purchased | 4,356,918 shares of Series Seed-1 Preferred Stock |
| Price Per Share | $2.2952 |
| Total Investment Value | Approximately $10.00 million (4,356,918 shares x $2.2952) |
Material Changes and Strategic Agreements
On January 26, 2026, ASP Isotopes entered into a Series Seed-1 Preferred Stock Purchase Agreement with Opeongo, Inc. Key terms include:
- Investment Purpose: Opeongo develops therapeutics using extracellular matrix (ECM) modulation for fibrosis, inflammation, and cancer.
- Supply Agreement: Within 30 days, the parties must negotiate a supply agreement granting ASP Isotopes a right of first offer for medical isotopes used in Opeongo's pharmaceutical products.
- Related Party Transactions: The agreement involves related parties, including Paul Mann (ASP Isotopes CEO and Opeongo Director) and Todd Wider (ASP Isotopes Director and Opeongo CMO).
Investor Rights and Governance
As part of the investment, ASP Isotopes secured significant governance rights in Opeongo:
- Board Representation: Right to elect and remove one director (initially designated as Paul Mann) as long as at least 2,178,459 shares of Series Seed-1 Preferred Stock remain outstanding.
- Conversion Rights: Shares are convertible to common stock at the original purchase price ($2.2952), subject to anti-dilution adjustments. Automatic conversion occurs upon a qualified public offering (minimum $50 million gross proceeds).
- Protective Provisions: Veto rights regarding major corporate actions.
- Additional Agreements: Execution of Investors' Rights Agreement, Right of First Refusal and Co-Sale Agreement, and Voting Agreement.
Investor Verification Checklist
- Verify the total cash outflow for the $10 million investment and its impact on ASP Isotopes' current liquidity position.
- Confirm the status of the related party disclosures regarding Paul Mann and Todd Wider to ensure compliance with conflict of interest policies.
- Monitor the negotiation progress of the supply agreement for medical isotopes, due within 30 days of the filing date.
- Review the full text of the Opeongo Charter and Investment Agreements (to be filed as exhibits to the 2025 Form 10-K) for detailed anti-dilution and redemption terms.
- Assess the strategic fit of Opeongo's ECM modulation pipeline with ASP Isotopes' core isotope business.